320 related articles for article (PubMed ID: 23401061)
1. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
2. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
3. A novel framework for interpretation of data from the fish short-term reproduction assay (FSTRA) for the detection of endocrine-disrupting chemicals.
Ankley GT; Jensen KM
Environ Toxicol Chem; 2014 Nov; 33(11):2529-40. PubMed ID: 25098918
[TBL] [Abstract][Full Text] [Related]
4. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
[TBL] [Abstract][Full Text] [Related]
5. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
6. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
[TBL] [Abstract][Full Text] [Related]
7. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
8. Summary of reference chemicals evaluated by the fish short-term reproduction assay, OECD TG229, using Japanese Medaka, Oryzias latipes.
Onishi Y; Tatarazako N; Koshio M; Okamura T; Watanabe H; Sawai A; Yamamoto J; Ishikawa H; Sato T; Kawashima Y; Yamazaki K; Iguchi T
J Appl Toxicol; 2021 Aug; 41(8):1200-1221. PubMed ID: 33486801
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
11. Summary of the development the US Environmental Protection Agency's Medaka Extended One Generation Reproduction Test (MEOGRT) using data from 9 multigenerational medaka tests.
Flynn K; Lothenbach D; Whiteman F; Hammermeister D; Touart LW; Swintek J; Tatarazako N; Onishi Y; Iguchi T; Johnson R
Environ Toxicol Chem; 2017 Dec; 36(12):3387-3403. PubMed ID: 28857258
[TBL] [Abstract][Full Text] [Related]
12. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
14. Environmental effect assessment for sexual endocrine-disrupting chemicals: Fish testing strategy.
Knacker T; Boettcher M; Frische T; Rufli H; Stolzenberg HC; Teigeler M; Zok S; Braunbeck T; Schäfers C
Integr Environ Assess Manag; 2010 Oct; 6(4):653-62. PubMed ID: 20872646
[TBL] [Abstract][Full Text] [Related]
15. In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds.
Fabian E; Gomes C; Birk B; Williford T; Hernandez TR; Haase C; Zbranek R; van Ravenzwaay B; Landsiedel R
Arch Toxicol; 2019 Feb; 93(2):401-416. PubMed ID: 30552464
[TBL] [Abstract][Full Text] [Related]
16. Gonadosomatic index as a confounding variable in fish-based screening assays for the detection of anti-estrogens and nonaromatizable androgens.
Roush KS; Jeffries MKS
Environ Toxicol Chem; 2019 Mar; 38(3):603-615. PubMed ID: 30614037
[TBL] [Abstract][Full Text] [Related]
17. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
18. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
19. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
20. Endocrine active agents: implications of adverse and non-adverse changes.
Foster PM; McIntyre BS
Toxicol Pathol; 2002; 30(1):59-65. PubMed ID: 11892727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
